LYTTON LAURENCE W 13D/13G Filings for Evoke Pharma, Inc. (EVOK)

LYTTON LAURENCE W 13D and 13G filings for Evoke Pharma, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2024-11-14
1:08 pm
Purchase
2024-09-3013GEvoke Pharma, Inc.
EVOK
LYTTON LAURENCE W74,757
9.990%
74,757increase
(New Position)
Filing